The Elle Foundation

Patients this resource is for you, when you are ready to get off psyche meds

20 Brutally Honest Truths About Psychiatry Click here if you need help quitting psychiatric medications: https://membership.taperclinic.com/sign-up- Get our free tapering course: https://membership.ta...

Dr. Harry Henshaw is an old friend, someone who has been mentoring me for 20 years. He is the best of the best in my book. He is good company, with a well earned spotlight (2020) Award for Excellence, the year Telehealth was recognized as the most pivatal gain in recovery resource. He brings cognitive behavioral guidance to the recovery world, each morning over zoom. Check out his book on Amazon or on EnhancedHealing.com And look for the link to his daily 7am recovery group.

GREAT GENOMIC OPPORTUNITY FOR FREE GENETIC TESTING AND COUNSELING.

Understanding Genetics Study offering genetic testing and counseling at no cost for people with Parkinson’s disease.

This morning i am thinking about Dr. Panayotis Thanos, the 2025 elle foundation award of excellence recipient and i am reflecting upon his contributions, wanting to ask how can i live my best to life, focused upon wellbeing, while attending to my Reward Deficiency Syndrome neurogenetic challenge.

Artificial Intelligence says the "Core Framework of Thanos research and theoretical contributions place Reward Deficiency as the Root of Vulnerability."
Thanos’ research consistently supports the concept of Reward Deficiency Syndrome (RDS)—a state in which genetic variants and neurobiological disruptions reduce dopamine signaling, increasing vulnerability to addiction, compulsive behaviors, and emotional dysregulation.
With this said, i am already utilizing RDS solution technology, have done genetic testing, for neurological analysis of underlying neurobiological issues like dopamine deficiency, and serotonin deficiency to create an appropriate pharmacogenomic response to achieve an artificial dopamine homeostasis. Done that : CHECK!

In doing so it became clear that the medications i had been prescribed by traditional psychiatrists were INAPPROPRIATE FOR MY GENOME. so these were actually harming my brain and working against the fundamental goals of achieving natural dopamine homeostasis. I AM ADDRESSING THIS LEVEL OF RECOVERY NOW WITH SYNAP, an amino acid nutritional therapy, my own RDS Severity of Symptom Chart. i am working the RDS solution program that i created for myself based upon having access to the Kenneth Blum, Raj Badgaiyan, Mark Gold and Peter Thanos RDS Consortium of scientist protocol. CHECK!! HOW FORTUNATE AM I? SERIOUSLY

Moving up and onward to greater levels of mastery, and desiring more quality of life, more wellbeing, more time lived as my highest self ELLE, i am looking at his research on exercise. i will dig a little deeper so that i might formulate the proper question that i would to ask him. it is so incredible to have the opportunity to ask!!!

thank you Dr. Gold! For the full article go to PSYCHOLOGY TODAY
What’s Up with Molly (M**A) After the Executive Order? Some likely scenarios in FDA approval process for the empathogen M**A in PTSD.
KEY POINTS:
The recent presidential Executive Order on psychedelic therapies has intensified the debate on M**A.
M**A is the primary example of an empathogen—inducing empathy, openness, and interpersonal connection.
M**A is a drug of abuse and both promising and challenging medication for treating severe PTSD.
The Executive Order may reposition the VA/DoD as major research infrastructure for M**A studies.
Few compounds better illustrate the tension between therapeutic promise, regulatory skepticism, abuse liability, and political momentum surrounding post-traumatic stress disorder (PTSD) than the drug M**A, a drug that acts as both a stimulant and a hallucinogen (empathogen and an entactogen) known by the street names Ecstasy and Molly. At one time primarily associated with rave culture, it is used to change energy, mood, empathy, distort time perception, and enhance the enjoyment of tactile experiences and pleasure. M**A continues to be studied as a potentially transformative psychiatric intervention for PTSD.
The recent presidential Executive Order on psychedelic therapies did not legalize M**A, nor did it bypass FDA authority. Instead, it may have shifted where the future of psychedelic psychiatry will ultimately be decided. The Executive Order apparently repositions the Department of Veterans Affairs (VA) and the Department of Defense (DoD) as major research infrastructures for psychedelic medicine.
This means that the future of M**A-assisted therapy may depend less on advocacy groups and much more on whether federally supervised studies on veterans and active-duty military personnel demonstrate durable, standardized, and clinically meaningful outcomes.
From “Molly” to Medicine
Historically, M**A referred to pressed tablets sold in dance clubs, while “Molly” became shorthand for supposedly pure crystalline M**A. In reality, however, forensic analyses have repeatedly shown that illicit products sold as M**A are often adulterated with methamphetamine, synthetic cathinones, ketamine analogs, caffeine, co***ne, or fentanyl.
M**A became widely known as the “love drug” because of its empathogenic effects. Users frequently reported increased emotional openness, heightened interpersonal trust, reduced defensiveness, and stronger feelings of emotional connection. These same effects also raised concerns regarding emotional suggestibility, compromised judgment, and vulnerability to exploitation.
This double identity—as a possible therapeutic agent and a recreational drug of abuse—continues shaping M**A’s regulatory history.
As a recent editorial in the journal Lancet (2026) observed, the principal challenge facing psychedelic psychiatry is to “separate hope firmly from hype.” The editorial noted that psychedelic-assisted therapy trials remain difficult to blind effectively (or to hide what they are, so subjects can’t tell whether they took the study drug or the placebo). Importantly, however, the editorial characterized many FDA concerns regarding M**A-assisted psychotherapy as “remediable issues".
Why the FDA Rejected M**A in 2024
Early randomized trials demonstrated unusually large effect sizes in patients with severe and treatment-resistant PTSD, including veterans, first responders, and survivors of chronic trauma. Phase-2 and Phase-3 studies showed substantial reductions in Clinician-Administered PTSD Scale (CAPS) scores, and the pivotal MAPP1 trial published in Nature Medicine in 2021 became a landmark for psychedelic psychiatry.
Despite this impetus, the FDA declined to approve M**A-assisted therapy in 2024.
10 Reasons Why The FDA Rejected M**A
10 Reasons Why The FDA Rejected M**A
Source: Mark Gold, MD, with permission
The FDA was less concerned with M**A's positive effects in PTSD but on methodological weaknesses, compromised blinding, psychotherapy standardization issues, safety-reporting limitations, therapist misconduct allegations, data integrity, and the durability and overall benefit–risk profile of M**A-assisted therapy.
Why Israeli PTSD Research Matters
Israel provides an important perspective through which to understand the next phase of M**A research. Israeli psychiatrists and trauma specialists have extensive experience treating combat veterans, terrorism survivors, and civilians exposed to chronic threat environments and have reported on treatments and outcomes from the Yom Kippur War. Israeli military psychiatry emphasizes immediate field assessment and proximity-based intervention following traumatic exposure, with the goal of restoring function early and reducing progression to PTSD.
Israeli researchers helped conduct some of the early studies of M**A-assisted therapy. However, even in Israel, M**A treatment is still tightly controlled and used mainly for patients with severe PTSD who have not improved with standard treatments.
What makes the Israeli experience especially important is its emphasis on functional restoration rather than symptom reduction alone. Israeli military psychiatry traditionally focuses on resilience, operational performance, interpersonal cohesion, immediate field intervention after traumatic exposure, and rapid return to military role/function. Israeli experts use M**A as a catalyst to temporarily reduce fear and defensiveness sufficiently to improve engagement with psychotherapy.
Why VA and DoD Studies May Become Decisive
After the president’s Executive Order, many believe the most consequential studies in the United States will likely occur within the VA and DoD systems. In contrast to smaller civilian psychedelic trials, the federal systems provide centralized medical records, standardized psychotherapy pathways, long-term follow-up, neurocognitive assessment, suicidality monitoring, and highly characterized trauma populations.
Importantly, military psychiatry evaluates outcomes differently from many civilian programs. The central question is not simply whether patients begin to feel better but whether they can function safely and effectively under high-stress military working conditions. Improved function is important, but resuming normal functioning is better.
Future Pentagon-backed M**A studies are expected to examine outcomes such as emotional control under stress, sleep restoration, cognitive performance, suicide-risk reduction, interpersonal functioning, return-to-duty capacity, and durability of benefit after repeated stress exposure.
These trials may also address several methodological weaknesses identified during the FDA review process. Standardized therapist training, tighter protocol enforcement, centralized adverse-event reporting, biomarker integration, and prolonged longitudinal follow-up may ultimately generate evidence that regulators view as more rigorous and reproducible.
Separating Psychedelic Medicine from the Illicit M**A Market
The Executive Order does not legalize illicit M**A, nor does it diminish ongoing public-health concerns. The 2025 Drug Enforcement Administration's National Drug Threat Assessment categorizes M**A usage as relatively low compared to drugs like fentanyl, methamphetamine, and co***ne. However, M**A remains widely abused by adolescents and young adults, produced by clandestine synthetic labs, and shipped to the U.S by transnational trafficking networks. The DEA warns that many substances sold as “Ecstasy” contain little or no M**A at all.
The distinction is critical. Pharmaceutical M**A research involves verified purity, known dosing, medical screening, and supervised administration. Illicit Molly or Ecstasy, by contrast, frequently reflects an unpredictable clandestine market with unknown pharmacologic composition.
The Future of Psychedelic Psychiatry
Psychedelic psychiatry is increasingly moving away from countercultural enthusiasm and toward large-scale federal research systems, randomized clinical trials, uniform protocols, formal regulatory scrutiny, biomarker-driven neuroscience, and longitudinal outcome analysis.

I AM GOING TO ORDER MORE COPIES. THIS IS ONE TO PASS AROUND TO YOUR LOVED ONES WHO NEED MORE THAN TRADITIONAL TWELVE STEPS CAN OFFER. STEP UP TO NEUROSCIENCE AND REWARD DEFICIENCY SYNDROME SOLUTION TREATMENT.

http://www.psychologytoday.com/profile/1396623

Dr. Edward J Modestino, Phd available for Mental Health Counseling, 2026 Elle Foundation Award for Excellence in Neuroscience and Mental Health Counseling.

EDWARD J MODESTINO, PHD
HTTP://WWW.MODESTINO-COUNSELING.COM/

GOOD MORNING RECOVERY WORLD!! I HAVE 2 GREAT RESOURCES FOR YOU, PRACTITIONERS IN PSYCHIATRY AND PSYCHOLOGY WHO HAVE TRAINING FROM BOTH THE TRADITIONAL AND GENOMIC ERAS. BOTH ARE TREATING PATIENTS ONLINE VIA TELEHEALTH.

ELLE FOUNDATION AWARDS FOR EXCELLENCE AND LIFETIME ACHIEVEMENT IN 2026 ARE BEING AWARDED TO 1) DR EDWARD JUSTINE MODESTINO, WHO CAN BE FOUND THROUGH PSYCHOLOGY TODAY. HE IS A LICENSED MENTAL HEALTH THERAPIST. AND 2) DR. IGOR ELMAN, A PSYCHIATRIST WHO HAS PATENTED PTSD TREATMENT. DR ELMAN IS ATTENDING TO THE PASSING OF A LOVED ONE MOMENTARILY BUT YOU CAN CALL DR MODESTINO AND GET ON HIS SCHEDULE NOW!!

The Elle Foundation wishes to thank 2024 Elle Foundation Award of Excellence recipient in psychiatric science, the great Dr. Radjendra Badgaiyan for calling in yesterday to check up on Case Study 101's progress. She has outgrown traditional psychiatry. it is no longer in her best interests to view her challenges through a traditional lens, which identifies mental health disorder. in the genomic era, we like to think of neurodivergent challenges and gifts and address any neurotransmitter imbalance through the lens of the Reward Deficiency Syndrome paradigm. Thank you Dr. Badgaiyan for taking the lead role as genetic psychiatrist in this ongoing longitudinal study. our participant is NO LONGER A MENTAL HEALTH DISORDER CLUSTER PATIENT, SHE IS THRIVING!!!